CL2019000190A1 - Tratamiento y prevención de los trastornos del sueño. - Google Patents
Tratamiento y prevención de los trastornos del sueño.Info
- Publication number
- CL2019000190A1 CL2019000190A1 CL2019000190A CL2019000190A CL2019000190A1 CL 2019000190 A1 CL2019000190 A1 CL 2019000190A1 CL 2019000190 A CL2019000190 A CL 2019000190A CL 2019000190 A CL2019000190 A CL 2019000190A CL 2019000190 A1 CL2019000190 A1 CL 2019000190A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- prevention
- sleep disorders
- animal
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Acoustics & Sound (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
LA DESCRIPCIÓN SE REFIERE A MÉTODOS PARA TRATAR O PREVENIR UN TRASTORNO DEL SUEÑO POR ADMINISTRACIÓN DE UN COMPUESTO DE LA FÓRMULA (1) (1) O UN COMPUESTO DE LA FÓRMULA (1A), (1B), (1C), (1D), (1E), O (1F) A UN ANIMAL QUE NECESITA DE TAL TRATAMIENTO. EN DETERMINADAS MODALIDADES, TALES COMPUESTOS TRATAN O PREVIENEN DE MODO EFICAZ UN TRASTORNO DEL SUEÑO EN EL ANIMAL, MIENTRAS SE PRODUCEN MENOS CANTIDAD DE EFECTOS COLATERALES EN COMPARACIÓN CON COMPUESTOS PREVIAMENTE DISPONIBLES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662366960P | 2016-07-26 | 2016-07-26 | |
US201762536097P | 2017-07-24 | 2017-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019000190A1 true CL2019000190A1 (es) | 2019-06-07 |
Family
ID=59714072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019000190A CL2019000190A1 (es) | 2016-07-26 | 2019-01-25 | Tratamiento y prevención de los trastornos del sueño. |
Country Status (20)
Country | Link |
---|---|
US (3) | US10974081B2 (es) |
EP (1) | EP3490563A1 (es) |
JP (2) | JP7198197B2 (es) |
KR (2) | KR102210209B1 (es) |
CN (1) | CN109689058B (es) |
AU (2) | AU2017304898B2 (es) |
BR (1) | BR112019001457A2 (es) |
CA (1) | CA3031388C (es) |
CL (1) | CL2019000190A1 (es) |
EC (1) | ECSP19014247A (es) |
IL (1) | IL264294B (es) |
JO (1) | JOP20190008A1 (es) |
MX (1) | MX2019001036A (es) |
NZ (1) | NZ750817A (es) |
PH (1) | PH12019500177A1 (es) |
SG (1) | SG11201900486WA (es) |
TN (1) | TN2019000019A1 (es) |
TW (1) | TWI661827B (es) |
WO (1) | WO2018020418A1 (es) |
ZA (1) | ZA201901055B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190008A1 (ar) * | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
MX2020007817A (es) | 2018-01-24 | 2020-09-25 | Purdue Pharma Lp | Prevención y tratamiento del trastorno del sueño. |
KR102198846B1 (ko) * | 2018-06-29 | 2021-01-05 | 다인기술 주식회사 | 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체 |
CN111359074B (zh) * | 2018-12-26 | 2022-08-02 | 财团法人工业技术研究院 | 个人化参数学习方法、睡眠辅助装置及存储介质 |
US11547350B2 (en) | 2018-12-26 | 2023-01-10 | Industrial Technology Research Institute | Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium |
EP3917621A1 (en) * | 2019-01-31 | 2021-12-08 | Purdue Pharma LP | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound |
CN114555083A (zh) * | 2019-09-13 | 2022-05-27 | 武田药品工业株式会社 | 食欲素2受体激动剂用于治疗过度嗜睡的用途 |
TWI804037B (zh) * | 2021-11-02 | 2023-06-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 生酮飲食之評估系統及其運作方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
DE69635048T2 (de) | 1995-06-12 | 2006-02-16 | G.D. Searle & Co. | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
US6572891B1 (en) | 1999-10-23 | 2003-06-03 | Alkaloid Ad | Sublingual oral dosage form |
DK1491212T3 (da) | 2002-03-29 | 2012-10-29 | Mitsubishi Tanabe Pharma Corp | Middel til behandling af søvnforstyrrelser |
US7749533B2 (en) | 2003-05-07 | 2010-07-06 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
US8067603B2 (en) | 2003-09-25 | 2011-11-29 | Solvay Pharmaceuticals B.V. | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors |
US7355045B2 (en) | 2004-01-05 | 2008-04-08 | Applera Corporation | Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof |
WO2006025267A1 (ja) | 2004-08-31 | 2006-03-09 | Mitsubishi Pharma Corporation | Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬 |
WO2008033024A2 (en) | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
EP3564240B1 (en) * | 2007-08-31 | 2022-04-06 | Purdue Pharma L.P. | Piperidine intermediates |
WO2009113703A2 (en) | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
AU2009275218C1 (en) * | 2008-07-21 | 2015-02-05 | Purdue Pharma L.P. | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the uses thereof |
ES2583146T3 (es) | 2011-12-01 | 2016-09-19 | Purdue Pharma L.P. | Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos |
US10118927B2 (en) | 2012-12-27 | 2018-11-06 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
WO2014102592A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof |
JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
-
2017
- 2017-06-16 JO JOP/2019/0008A patent/JOP20190008A1/ar unknown
- 2017-07-25 SG SG11201900486WA patent/SG11201900486WA/en unknown
- 2017-07-25 WO PCT/IB2017/054506 patent/WO2018020418A1/en unknown
- 2017-07-25 TN TNP/2019/000019A patent/TN2019000019A1/en unknown
- 2017-07-25 KR KR1020197004527A patent/KR102210209B1/ko active IP Right Grant
- 2017-07-25 JP JP2019503994A patent/JP7198197B2/ja active Active
- 2017-07-25 CN CN201780046414.XA patent/CN109689058B/zh active Active
- 2017-07-25 NZ NZ750817A patent/NZ750817A/en unknown
- 2017-07-25 MX MX2019001036A patent/MX2019001036A/es unknown
- 2017-07-25 KR KR1020217002556A patent/KR102531366B1/ko active IP Right Grant
- 2017-07-25 EP EP17758282.2A patent/EP3490563A1/en active Pending
- 2017-07-25 TW TW106124940A patent/TWI661827B/zh active
- 2017-07-25 AU AU2017304898A patent/AU2017304898B2/en active Active
- 2017-07-25 CA CA3031388A patent/CA3031388C/en active Active
- 2017-07-25 US US16/318,686 patent/US10974081B2/en active Active
- 2017-07-25 BR BR112019001457-8A patent/BR112019001457A2/pt not_active Application Discontinuation
-
2019
- 2019-01-17 IL IL264294A patent/IL264294B/en unknown
- 2019-01-25 PH PH12019500177A patent/PH12019500177A1/en unknown
- 2019-01-25 CL CL2019000190A patent/CL2019000190A1/es unknown
- 2019-02-19 ZA ZA2019/01055A patent/ZA201901055B/en unknown
- 2019-02-26 EC ECSENADI201914247A patent/ECSP19014247A/es unknown
-
2020
- 2020-11-19 AU AU2020273332A patent/AU2020273332B2/en active Active
-
2021
- 2021-03-08 US US17/195,434 patent/US11738023B2/en active Active
- 2021-04-21 JP JP2021072166A patent/JP7291172B2/ja active Active
-
2023
- 2023-06-28 US US18/343,182 patent/US20240058333A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000190A1 (es) | Tratamiento y prevención de los trastornos del sueño. | |
CL2018003429A1 (es) | Compuestos novedosos como inhibidores de la autotaxina y composiciones farmacéuticas que los comprenden. | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
ECSP18024971A (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma | |
CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
BR112018003212A2 (pt) | diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 | |
NZ722326A (en) | Tricyclic compounds as anticancer agents | |
CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
MX2019005779A (es) | Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina. | |
DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
MX2019009292A (es) | Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi. | |
MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
BR112017027277A2 (pt) | ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula? | |
CL2017000118A1 (es) | Métodos y composiciones para tratar desórdenes relacionados con el vih | |
MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
CL2021000660A1 (es) | Compuestos quelantes de hierro para tratar condiciones estéticas de la piel | |
CL2020000586A1 (es) | Moduladores de la expresión de enac. | |
AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño | |
MX2020011766A (es) | Metodos de administracion de tratamiento antifibrotico. | |
EA201891008A2 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
CL2021000743A1 (es) | Métodos para tratar trastornos mieloproliferativos |